drugset / Trial / NCT00475358

Efficacy and Safety Stress Urinary Incontinence Study

NCT00475358

Phase 3 Completed 120 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.

Timeline

Start
2003-04
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 80 mg